Random Checks Now Routine: China To Inspect Your Factories Near And Far
An officially released new regulation in China legalizes overseas inspections of drug and device makers, making the risk-based inspections routine tasks that could also expand to manufacturers' R&D partners and third-party suppliers of ingredients, excipients or packaging materials.
You may also be interested in...
From heightened overseas manufacturing inspections to a new patent challenge mechanism, important regulatory changes are coming in China this year, and implementation could potentially derail your operations in this key market.
While many pharma firms in China choose to partner with US companies, Jiangsu Hengrui is relying on itself to go global. The Chinese pharma giant is betting on its newly established US subsidiary Luzsana in a major move to make its wide-ranging products more available, accessible and affordable to patients in the US and the rest of the world.
Home-grown Chinese mRNA COVID-19 vaccines are more effective than domestic inactivated virus-based shots, new trial results show.